353 related articles for article (PubMed ID: 33392850)
1. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
[TBL] [Abstract][Full Text] [Related]
2. Multiple endocrine neoplasia type 2.
Lodish M
Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
4. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
[TBL] [Abstract][Full Text] [Related]
5. [Multiple endocrine neoplasia syndromes. Type 2].
Juodele L; Juozaityte E; Zindzius A; Pundzius J
Medicina (Kaunas); 2005; 41(4):281-94. PubMed ID: 15864001
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
7. [Genotype-phenotype correlations in multiple endocrine neoplasia type 2].
Zhang XW; Wang JY; Zhang YB; Wan HF; Zhang B; Yan DG; Liu WS; Xu ZG; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jul; 51(7):538-41. PubMed ID: 27480304
[TBL] [Abstract][Full Text] [Related]
8. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA; Pacini F; Robinson BG; Santoro M
J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408
[TBL] [Abstract][Full Text] [Related]
9. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic procedures in the follow-up of patients affected by MEN type 2.
Seregni E; Pallotti F; Mattavelli F; Ferrari L; Martinetti A; Aliberti G; Villano C; Castellani MR; Bombardieri E
Tumori; 2003; 89(5):563-5. PubMed ID: 14870788
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
[TBL] [Abstract][Full Text] [Related]
12. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
14. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
15. Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.
Wang YP; Li FP; Wang HH; Fang XD; Zhu ZS; Chen YL; Qi XP
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):339-347. PubMed ID: 34445950
[TBL] [Abstract][Full Text] [Related]
16. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B.
O'Riordain DS; O'Brien T; Weaver AL; Gharib H; Hay ID; Grant CS; van Heerden JA
Surgery; 1994 Dec; 116(6):1017-23. PubMed ID: 7985081
[TBL] [Abstract][Full Text] [Related]
18. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.
Raue F; Frank-Raue K
Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]